Amylyx Pharmaceuticals Inc AMLX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AMLX is a good fit for your portfolio.
News
-
Investigation Alert Amylyx, Hut 8, Xponential Fitness, and iRhythm Technologies: Submit Your Information Now to Johnson Fistel, LLP
-
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
-
DEADLINE ALERT for XPOF, LUXH, and AMLX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
-
The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLX
-
Amylyx Pharmaceuticals, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 9, 2024 deadline
-
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)
-
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMLX
-
AMLX DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action – AMLX
Trading Information
- Previous Close Price
- $1.78
- Day Range
- $1.70–1.84
- 52-Week Range
- $1.70–30.50
- Bid/Ask
- $1.77 / $1.84
- Market Cap
- $119.69 Mil
- Volume/Avg
- 5.2 Mil / 3.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- 1.49
- Price/Sales
- 0.32
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 384
- Website
- https://www.amylyx.com
Comparables
Valuation
Metric
|
AMLX
|
ICVX
|
MRNS
|
---|---|---|---|
Price/Earnings (Normalized) | 1.49 | — | — |
Price/Book Value | 0.27 | 3.30 | 4.62 |
Price/Sales | 0.32 | — | 2.46 |
Price/Cash Flow | 1.59 | — | — |
Price/Earnings
AMLX
ICVX
MRNS
Financial Strength
Metric
|
AMLX
|
ICVX
|
MRNS
|
---|---|---|---|
Quick Ratio | 5.01 | 17.59 | 3.79 |
Current Ratio | 5.66 | 18.06 | 4.07 |
Interest Coverage | — | — | −7.94 |
Quick Ratio
AMLX
ICVX
MRNS
Profitability
Metric
|
AMLX
|
ICVX
|
MRNS
|
---|---|---|---|
Return on Assets (Normalized) | 18.55% | −29.30% | −59.45% |
Return on Equity (Normalized) | 21.48% | −31.87% | −195.80% |
Return on Invested Capital (Normalized) | 17.45% | −34.69% | −84.00% |
Return on Assets
AMLX
ICVX
MRNS
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ndgvmhdrk | Sbl | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Yjmbkbd | Rscvm | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ppldrvrwl | Pjgtj | $97.8 Bil | |
MRNA
| Moderna Inc | Zvwvgkct | Tzxcb | $41.3 Bil | |
ARGX
| argenx SE ADR | Bsjvxzmh | Dtcg | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Qbpzkjy | Mpmr | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zrsdqxpr | Yhmbrm | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kjdtnwq | Knqldt | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ngtrpysph | Zvfmpdd | $12.5 Bil | |
INCY
| Incyte Corp | Ddnvjxgft | Jtvwk | $11.6 Bil |